Join
ContextLogic Inc. logo

LOGC

NASDAQ

ContextLogic Inc.

SectorConsumer DiscretionaryIndustryCatalog/Specialty DistributionIPO2020
$7.05+0.07 (+1.00%)
News25/Ratings5

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Price$7.05+0.00 (+0.00%)
2026-02-272026-06-02
News · 26 weeks49+80%
2025-12-14: 02025-12-21: 02025-12-28: 02026-01-04: 02026-01-11: 02026-01-18: 102026-01-25: 02026-02-01: 02026-02-08: 02026-02-15: 02026-02-22: 102026-03-01: 52026-03-08: 12026-03-15: 22026-03-22: 02026-03-29: 52026-04-05: 12026-04-12: 12026-04-19: 02026-04-26: 22026-05-03: 02026-05-10: 32026-05-17: 22026-05-24: 12026-05-31: 62026-06-07: 0
2025-12-142026-06-07
Mix2490d
  • Insider12(50%)
  • SEC Filings8(33%)
  • Leadership2(8%)
  • M&A1(4%)
  • Other1(4%)

Latest news

25 items

LOGC FAQ

7 questions
  • What does ContextLogic Inc. do?
    LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as...
  • Where does LOGC stock trade?
    ContextLogic Inc. (LOGC) is listed on NASDAQ.
  • What sector and industry is LOGC in?
    ContextLogic Inc. operates in the Consumer Discretionary sector, Catalog/Specialty Distribution industry.
  • When did ContextLogic Inc. go public?
    ContextLogic Inc. (LOGC) completed its IPO in 2020.
  • What are analysts saying about LOGC?
    ContextLogic Inc. has had 5 recent analyst actions on file. The most recent action was from William Blair: Market Perform on 2022-02-03. Recent price targets range from $600.00 to $1600.00.
  • What companies are similar to LOGC?
    Notable peers in the same industry include AMZN (Amazon.com Inc.), CPNG (Coupang Inc.), OZON (Ozon Holdings PLC), W (Wayfair Inc.), CHWY (Chewy Inc.). Compare LOGC side-by-side with any of them on Quantisnow.
  • How can I track LOGC on Quantisnow?
    Quantisnow aggregates ContextLogic Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LOGC to receive live email and push alerts on every new disclosure.